We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Merck (MRK - Free Report) was down 1.3% at $119.28. The stock's performance was behind the S&P 500's daily gain of 0.08%. On the other hand, the Dow registered a loss of 0.18%, and the technology-centric Nasdaq increased by 0.1%.
Shares of the pharmaceutical company witnessed a gain of 3.19% over the previous month, beating the performance of the Medical sector with its loss of 6.98%, and the S&P 500's loss of 1.74%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on April 30, 2026. It is anticipated that the company will report an EPS of -$0.57, marking a 125.68% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $16.01 billion, reflecting a 3.09% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $5.26 per share and a revenue of $66.68 billion, demonstrating changes of -41.43% and +2.57%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 4.35% fall in the Zacks Consensus EPS estimate. Merck is holding a Zacks Rank of #3 (Hold) right now.
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 22.96. This valuation marks a premium compared to its industry average Forward P/E of 14.22.
We can also see that MRK currently has a PEG ratio of 2.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.34.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 156, this industry ranks in the bottom 37% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
In the latest close session, Merck (MRK - Free Report) was down 1.3% at $119.28. The stock's performance was behind the S&P 500's daily gain of 0.08%. On the other hand, the Dow registered a loss of 0.18%, and the technology-centric Nasdaq increased by 0.1%.
Shares of the pharmaceutical company witnessed a gain of 3.19% over the previous month, beating the performance of the Medical sector with its loss of 6.98%, and the S&P 500's loss of 1.74%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on April 30, 2026. It is anticipated that the company will report an EPS of -$0.57, marking a 125.68% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $16.01 billion, reflecting a 3.09% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $5.26 per share and a revenue of $66.68 billion, demonstrating changes of -41.43% and +2.57%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 4.35% fall in the Zacks Consensus EPS estimate. Merck is holding a Zacks Rank of #3 (Hold) right now.
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 22.96. This valuation marks a premium compared to its industry average Forward P/E of 14.22.
We can also see that MRK currently has a PEG ratio of 2.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.34.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 156, this industry ranks in the bottom 37% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.